Quoin Pharmaceuticals Ltd Stock Analysis
| QNRX Stock | USD 0.28 0.02 6.67% |
Quoin Pharmaceuticals Ltd is undervalued with Real Value of 1.33 and Target Price of 4.5. The main objective of Quoin Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Quoin Pharmaceuticals Ltd is worth, separate from its market price. There are two main types of Quoin Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Quoin Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Quoin Pharmaceuticals is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Quoin Stock trading window is adjusted to America/New York timezone.
Quoin |
Quoin Stock Analysis Notes
The company has price-to-book ratio of 0.63. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Quoin Pharmaceuticals recorded a loss per share of 2.0. The entity last dividend was issued on the 23rd of October 2019. The firm had 1:12 split on the 18th of July 2023. Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Quoin Pharmaceuticals, Ltd. was incorporated in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people. To find out more about Quoin Pharmaceuticals Ltd contact Michael Myers at 703 980 4182 or learn more at https://quoinpharma.com.Quoin Pharmaceuticals Investment Alerts
| Quoin Pharmaceuticals generated a negative expected return over the last 90 days | |
| Quoin Pharmaceuticals has high historical volatility and very poor performance | |
| Quoin Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Quoin Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Quoin Pharmaceuticals Ltd currently holds 6.5 B in liabilities with Debt to Equity (D/E) ratio of 0.47, which is about average as compared to similar companies. Quoin Pharmaceuticals has a current ratio of 0.94, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Quoin Pharmaceuticals' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (8.96 B) with profit before overhead, payroll, taxes, and interest of 0. | |
| Quoin Pharmaceuticals Ltd currently holds about 2.69 M in cash with (7.86 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.56, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from simplywall.st: Improved Revenues Required Before Hvsen Biotechnology Co., Ltd. Stocks 30 percent Jump Looks Justified |
Quoin Pharmaceuticals Upcoming and Recent Events
Earnings reports are used by Quoin Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 13th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Quoin Largest EPS Surprises
Earnings surprises can significantly impact Quoin Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-05-08 | 2023-03-31 | -0.28 | -0.34 | -0.06 | 21 | ||
2025-03-11 | 2024-12-31 | -0.43 | -0.2781 | 0.1519 | 35 | ||
2023-03-08 | 2022-12-31 | -0.62 | -0.41 | 0.21 | 33 |
Quoin Stock Institutional Investors
| Shares | Ubs Group Ag | 2024-12-31 | 4.8 K | Sbi Securities Co Ltd | 2024-12-31 | 24.0 | Raiffeisen Bank International Ag | 2024-12-31 | 17.0 | Resources Investment Advisors Inc | 2024-09-30 | 0.0 | Susquehanna International Group, Llp | 2024-09-30 | 0.0 | Jpmorgan Chase & Co | 2024-12-31 | 0.0 | Two Sigma Investments Llc | 2024-09-30 | 0.0 | Virtu Financial Llc | 2024-12-31 | 0.0 | Bank Of America Corp | 2024-09-30 | 0.0 | Armistice Capital, Llc | 2024-12-31 | 530 K | Altium Capital Management, Lp | 2024-12-31 | 282.2 K |
Quoin Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.07 M.Quoin Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.59) | (0.56) | |
| Return On Capital Employed | (1.26) | (1.32) | |
| Return On Assets | (0.57) | (0.54) | |
| Return On Equity | (0.97) | (1.02) |
Management Efficiency
Quoin Pharmaceuticals has return on total asset (ROA) of (0.4272) % which means that it has lost $0.4272 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2056) %, meaning that it created substantial loss on money invested by shareholders. Quoin Pharmaceuticals' management efficiency ratios could be used to measure how well Quoin Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -0.56 in 2025. Return On Capital Employed is likely to drop to -1.32 in 2025. At this time, Quoin Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 822.5 M in 2025, despite the fact that Other Assets are likely to grow to (61.56).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2 K | 1.6 K | |
| Tangible Book Value Per Share | 1.9 K | 1.6 K | |
| Enterprise Value Over EBITDA | (0.25) | (0.26) | |
| Enterprise Value Multiple | (0.25) | (0.26) | |
| Enterprise Value | -3.6 B | -3.4 B |
The strategic initiatives led by Quoin Pharmaceuticals' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Technical Drivers
As of the 27th of March, Quoin Pharmaceuticals holds the Coefficient Of Variation of (954.71), variance of 63.05, and Risk Adjusted Performance of (0.08). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Quoin Pharmaceuticals, as well as the relationship between them.Quoin Pharmaceuticals Price Movement Analysis
The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Quoin Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Quoin Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Quoin Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Quoin Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Quoin Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Quoin Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Michael Myers over six months ago Acquisition by Michael Myers of 5322 shares of Quoin Pharmaceuticals at 0.6558 subject to Rule 16b-3 | ||
Michael Myers over six months ago Acquisition by Michael Myers of 800 shares of Quoin Pharmaceuticals at 0.619 subject to Rule 16b-3 | ||
Langer Dennis over six months ago Disposition of 297 shares by Langer Dennis of Quoin Pharmaceuticals at 0.732 subject to Rule 16b-3 | ||
Denise Carter over a year ago Acquisition by Denise Carter of 80966 shares of Quoin Pharmaceuticals subject to Rule 16b-3 | ||
Cooper Joseph Patrick over a year ago Quoin Pharmaceuticals exotic insider transaction detected |
Quoin Pharmaceuticals Outstanding Bonds
Quoin Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Quoin Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Quoin bonds can be classified according to their maturity, which is the date when Quoin Pharmaceuticals Ltd has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Quoin Pharmaceuticals Predictive Daily Indicators
Quoin Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Quoin Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Quoin Pharmaceuticals Forecast Models
Quoin Pharmaceuticals' time-series forecasting models are one of many Quoin Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Quoin Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Quoin Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Quoin Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Quoin shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Quoin Pharmaceuticals. By using and applying Quoin Stock analysis, traders can create a robust methodology for identifying Quoin entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (49.23) | (51.69) | |
| Operating Profit Margin | (49.23) | (51.69) | |
| Net Loss | (49.23) | (51.69) | |
| Gross Profit Margin | 1.30 | 1.10 |
Current Quoin Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Quoin analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Quoin analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 4.5 | Strong Buy | 2 | Odds |
Most Quoin analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Quoin stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Quoin Pharmaceuticals, talking to its executives and customers, or listening to Quoin conference calls.
Quoin Stock Analysis Indicators
Quoin Pharmaceuticals Ltd stock analysis indicators help investors evaluate how Quoin Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Quoin Pharmaceuticals shares will generate the highest return on investment. By understating and applying Quoin Pharmaceuticals stock analysis, traders can identify Quoin Pharmaceuticals position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 2.4 M | |
| Common Stock Shares Outstanding | 4.7 M | |
| Total Stockholder Equity | 9.2 B | |
| Cash And Short Term Investments | 3.6 B | |
| Cash | 3.6 B | |
| Accounts Payable | 905.7 K | |
| Net Debt | -3.6 B | |
| 50 Day M A | 0.3512 | |
| Total Current Liabilities | 4.2 B | |
| Non Current Assets Total | 783.3 M | |
| Non Currrent Assets Other | 300 M | |
| Stock Based Compensation | 1.3 B |
Additional Tools for Quoin Stock Analysis
When running Quoin Pharmaceuticals' price analysis, check to measure Quoin Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quoin Pharmaceuticals is operating at the current time. Most of Quoin Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Quoin Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quoin Pharmaceuticals' price. Additionally, you may evaluate how the addition of Quoin Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.